CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review

Cytokine

Volumn 77, Issue , 2016, Pages 227-237

  Kothur, Kavitha ^a   Wienholt, Louise ^b   Brilot, Fabienne ^a   Dale, Russell C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

ADEM; Autoantibodies; Autoimmune; Biomarkers; Chemokines; Cytokines; Encephalitis; Neuroinflammation

Indexed keywords

B CELL ACTIVATING FACTOR; CHEMOKINE; CXCL13 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; RANTES; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER; CXCL13 PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ALLERGIC ENCEPHALITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CYTOKINE PRODUCTION; HUMAN; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVOUS SYSTEM INFLAMMATION; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOUS; OPSOCLONUS MYOCLONUS SYNDROME; OPTIC NEURITIS; PRIORITY JOURNAL; PSYCHOPATHY; RASMUSSEN SYNDROME; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; TH2 CELL; VIRUS ENCEPHALITIS; AUTOIMMUNE DISEASES; CEREBROSPINAL FLUID; NERVOUS SYSTEM DISEASES; SENSITIVITY AND SPECIFICITY;

AUTOIMMUNE DISEASES; B-CELL ACTIVATING FACTOR; BIOMARKERS; CHEMOKINE CXCL13; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; NERVOUS SYSTEM DISEASES; SENSITIVITY AND SPECIFICITY;

EID: 84948773327     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.10.001     Document Type: Review

References (106)

1. Dale R.C., Brilot F. Biomarkers of inflammatory and auto-immune central nervous system disorders. Curr. Opin. Pediatr. 2010, 22(6):718-725.
2. Glaser C.A., Honarmand S., Anderson L.J., Schnurr D.P., Forghani B., Cossen C.K., et al. Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin. Infect. Dis.: Official Publ. Infect. Dis. Soc. Am. 2006, 43(12):1565-1577.
3. Pillai S.C., Hacohen Y., Tantsis E., Prelog K., Merheb V., Kesson A., et al. Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome. Pediatrics 2015, 135(4):e974-e984.
4. Rantalaiho T., Farkkila M., Vaheri A., Koskiniemi M. Acute encephalitis from 1967 to 1991. J. Neurol. Sci. 2001, 184(2):169-177.
5. Granerod J., Ambrose H.E., Davies N.W., Clewley J.P., Walsh A.L., Morgan D., et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect. Dis. 2010, 10(12):835-844.
6. Glaser C.A., Gilliam S., Schnurr D., Forghani B., Honarmand S., Khetsuriani N., et al. In search of encephalitis etiologies: diagnostic challenges in the California encephalitis project, 1998-2000. Clin. Infect. Dis.: Official Publ. Infect. Dis. Soc. Am. 2003, 36(6):731-742.
7. Dale R.C., Branson J.A. Acute disseminated encephalomyelitis or multiple sclerosis: can the initial presentation help in establishing a correct diagnosis?. Arch. Dis. Child 2005, 90(6):636-639.
8. Hanly J.G. Diagnosis and management of neuropsychiatric SLE. Nat. Rev. Rheumatol. 2014.
9. Pang K.K., de Sousa C., Lang B., Pike M.G. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur. J. Paediatric Neurol.: EJPN: Official J. Eur. Paediatric Neurol. Soc. 2010, 14(2):156-161.
10. Bien C.G., Granata T., Antozzi C., Cross J.H., Dulac O., Kurthen M., et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain: J. Neurol. 2005, 128(Pt 3):454-471.
11. Dale R.C., Brilot F., Fagan E., Earl J. Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation. Dev. Med. Child Neurol. 2009, 51(4):317-323.
12. Molero-Luis M., Fernandez-Urena S., Jordan I., Serrano M., Ormazabal A., Garcia-Cazorla A., et al. Cerebrospinal fluid neopterin analysis in neuropediatric patients: establishment of a new cut off-value for the identification of inflammatory-immune mediated processes. PLoS One 2013, 8(12):e83237.
13. Sinclair A.J., Wienholt L., Tantsis E., Brilot F., Dale R.C. Clinical association of intrathecal and mirrored oligoclonal bands in paediatric neurology. Dev. Med. Child Neurol. 2013, 55(1):71-75.
14. Hacohen Y., Singh R., Forsyth V., Absoud M., Lim M. CSF albumin and immunoglobulin analyses in childhood neurologic disorders. Neurol.(R) Neuroimmunol. Neuroinflammation 2014, 1(1):e10.
15. Lancaster E., Dalmau J. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat. Rev. Neurol. 2012, 8(7):380-390.
16. Peter J. Delves, S.J. Martin, D.R. Burton, I.M. Roitt, Roitt's Essential Immunology, 12th ed., Wiley-Blackwell, 2011.
17. Hemdan N.Y., Birkenmeier G., Wichmann G., Abu El-Saad A.M., Krieger T., Conrad K., et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun. Rev. 2010, 9(11):785-792.
18. Ma C.S., Deenick E.K. Human T follicular helper (Tfh) cells and disease. Immunol. Cell Biol. 2014, 92(1):64-71.
19. Akdis M., Burgler S., Crameri R., Eiwegger T., Fujita H., Gomez E., et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. J. Allergy Clin. Immunol. 2011, 127(3):701-721. e1-70.
20. Zlotnik A., Yoshie O. The chemokine superfamily revisited. Immunity 2012, 36(5):705-716.
21. Sallusto F., Lanzavecchia A., Mackay C.R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 1998, 19(12):568-574.
22. Lebre M.C., Burwell T., Vieira P.L., Lora J., Coyle A.J., Kapsenberg M.L., et al. Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol. Cell Biol. 2005, 83(5):525-535.
23. Mook-Kanamori B., van de Beek D., Wijdicks E.F. Herpes simplex encephalitis with normal initial cerebrospinal fluid examination. J. Am. Geriatr. Soc. 2009, 57(8):1514-1515.
24. Wang S.M., Lei H.Y., Yu C.K., Wang J.R., Su I.J., Liu C.C. Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. J. Infect. Dis. 2008, 198(7):1002-1006.
25. Lin T.Y., Hsia S.H., Huang Y.C., Wu C.T., Chang L.Y. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin. Infect. Dis.: Official Publ. Infect. Dis. Soc. Am. 2003, 36(3):269-274.
26. Wang S.M., Lei H.Y., Liu C.C. Cytokine immunopathogenesis of enterovirus 71 brain stem encephalitis. Clin. Dev. Immunol. 2012, 2012.
27. Kamei S., Taira N., Ishihara M., Sekizawa T., Morita A., Miki K., et al. Prognostic value of cerebrospinal fluid cytokine changes in herpes simplex virus encephalitis. Cytokine 2009, 46(2):187-193.
28. Rosler A., Pohl M., Braune H.J., Oertel W.H., Gemsa D., Sprenger H. Time course of chemokines in the cerebrospinal fluid and serum during herpes simplex type 1 encephalitis. J. Neurol. Sci. 1998, 157(1):82-89.
29. Aurelius E., Andersson B., Forsgren M., Skoldenberg B., Strannegard O. Cytokines and other markers of intrathecal immune-response in patients with herpes-simplex encephalitis. J. Infect. Dis. 1994, 170(3):678-681.
30. Ichiyama T., Morishima T., Isumi H., Matsufuji H., Matsubara T., Furukawa S. Analysis of cytokine levels and NF-kappaB activation in peripheral blood mononuclear cells in influenza virus-associated encephalopathy. Cytokine 2004, 27(1):31-37.
31. Winter P.M., Dung N.M., Loan H.T., Kneen R., Wills B., Thu L.T., et al. Proinflammatory cytokines and chemokines in humans with Japanese encephalitis. J. Infect. Dis. 2004, 190(9):1618-1626.
32. Kawamura Y., Yamazaki Y., Ohashi M., Ihira M., Yoshikawa T. Cytokine and chemokine responses in the blood and cerebrospinal fluid of patients with human herpesvirus 6B-associated acute encephalopathy with biphasic seizures and late reduced diffusion. J. Med. Virol. 2014, 86(3):512-518.
33. Kalita J., Srivastava R., Mishra M.K., Basu A., Misra U.K. Cytokines and chemokines in viral encephalitis: a clinicoradiological correlation. Neurosci. Lett. 2010, 473(1):48-51.
34. Ichiyama T., Nishikawa M., Yoshitomi T., Hayashi T., Furukawa S. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in cerebrospinal fluid from children with prolonged febrile seizures - comparison with acute encephalitis/encephalopathy. Neurology 1998, 50(2):407-411.
35. Piazza F., DiFrancesco J.C., Fusco M.L., Corti D., Pirovano L., Frigeni B., et al. Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. J. Neuroimmunol. 2010, 220(1-2):104-107.
36. Ito Y., Ichiyama T., Kimura H., Shibata M., Ishiwada N., Kuroki H., et al. Detection of influenza virus RNA by reverse transcription-PCR and proinflammatory cytokines in influenza-virus-associated encephalopathy. J. Med. Virol. 1999, 58(4):420-425.
37. Kerr J.R., Barah F., Chiswick M.L., McDonnell G.V., Smith J., Chapman M.D., et al. Evidence for the role of demyelination, HLA-DR alleles, and cytokines in the pathogenesis of parvovirus B19 meningoencephalitis and its sequelae. J. Neurol. Neurosurg. Psychiatry 2002, 73(6):739-746.
38. Matsuzono Y., Narita M., Akutsu Y., Togashi T. Interleukin-6 in cerebrospinal fluid of patients with central nervous system infections. Acta Paediatr. 1995, 84(8):879-883.
39. Lepej S.Z., Misic-Majerus L., Jeren T., Rode O.D., Remenar A., Sporec V., et al. Chemokines CXCL10 and CXCL11 in the cerebrospinal fluid of patients with tick-borne encephalitis. Acta Neurol. Scand. 2007, 115(2):109-114.
40. Kant Upadhyay R. Biomarkers in Japanese encephalitis: a review. Biomed. Res. Int. 2013, 2013.
41. Ichiyama T., Ito Y., Kubota M., Yamazaki T., Nakamura K., Furukawa S. Serum and cerebrospinal fluid levels of cytokines in acute encephalopathy associated with human herpesvirus-6 infection. Brain Dev. 2009, 31(10):731-738.
42. Kimura A., Yoshikura N., Koumura A., Hayashi Y., Inuzuka T. B-cell-activating factor belonging to the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) levels in cerebrospinal fluid of patients with meningoencephalitis. J. Neurol. Sci. 2015, 352(1-2):79-83.
43. Hytonen J., Kortela E., Waris M., Puustinen J., Salo J., Oksi J. CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation. J. Neuroinflammation 2014, 11:103.
44. Wang S.M., Lei H.Y., Huang M.C., Su L.Y., Lin H.C., Yu C.K., et al. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J. Clin. Virol.: Official Publ. Pan Am. Soc. Clin. Virol. 2006, 37(1):47-52.
45. Shoji H. Clinical characteristics of non-herpetic limbic encephalitis. Brain and nerve = Shinkei kenkyu no shinpo 2010, 62(8):853-860.
46. Ichiyama T., Shoji H., Takahashi Y., Matsushige T., Kajimoto M., Inuzuka T., et al. Cerebrospinal fluid levels of cytokines in non-herpetic acute limbic encephalitis: comparison with herpes simplex encephalitis. Cytokine 2008, 44(1):149-153.
47. Asaoka K., Shoji H., Nishizaka S., Ayabe M., Abe T., Ohori N., et al. Non-herpetic acute limbic encephalitis: cerebrospinal fluid cytokines and magnetic resonance imaging findings. Intern. Med. 2004, 43(1):42-48.
48. Leypoldt F., Hoftberger R., Titulaer M.J., Armangue T., Gresa-Arribas N., Jahn H., et al. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor Encephalitis: a potential biomarker of treatment response. JAMA Neurol. 2014.
49. Dale R.C., Morovat A. Interleukin-6 and oligoclonal IgG synthesis in children with acute disseminated encephalomyelitis. Neuropediatrics 2003, 34(3):141-145.
50. Ichiyama T., Shoji H., Kato M., Sawaishi Y., Ozawa H., Matsubara T., et al. Cerebrospinal fluid levels of cytokines and soluble tumour necrosis factor receptor in acute disseminated encephalomyelitis. Eur. J. Pediatr. 2002, 161(3):133-137.
51. Leake J.A., Albani S., Kao A.S., Senac M.O., Billman G.F., Nespeca M.P., et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr. Infect. Dis. J. 2004, 23(8):756-764.
52. Franciotta D., Di Stefano A.L., Jarius S., Zardini E., Tavazzi E., Ballerini C., et al. Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. J. Neuroimmunol. 2011, 230(1-2):160-163.
53. Ishizu T., Minohara M., Ichiyama T., Kira R., Tanaka M., Osoegawa M., et al. CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis. J. Neuroimmunol. 2006, 175(1-2):52-58.
54. Franciotta D., Zardini E., Ravaglia S., Piccolo G., Andreoni L., Bergamaschi R., et al. Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis. J. Neurol. Sci. 2006, 247(2):202-207.
55. Modvig S., Degn M., Horwitz H., Cramer S.P., Larsson H.B., Wanscher B., et al. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS One 2013, 8(10):e77163.
56. Uzawa A., Mori M., Arai K., Sato Y., Hayakawa S., Masuda S., et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Multiple Sclerosis 2010, 16(12):1443-1452.
57. Narikawa K., Misu T., Fujihara K., Nakashima I., Sato S., Itoyama Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J. Neuroimmunol. 2004, 149(1-2):182-186.
58. Ishizu T., Osoegawa M., Mei F.J., Kikuchi H., Tanaka M., Takakura Y., et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain: J. Neurol. 2005, 128(Pt 5):988-1002.
59. Matsushita T., Tateishi T., Isobe N., Yonekawa T., Yamasaki R., Matsuse D., et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 2013, 8(4):e61835.
60. Tanaka M., Matsushita T., Tateishi T., Ochi H., Kawano Y., Mei F.J., et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 2008, 71(13):974-981.
61. Uzawa A., Mori M., Ito M., Uchida T., Hayakawa S., Masuda S., et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J. Neurol. 2009, 256(12):2082-2084.
62. Zhong X., Wang H., Dai Y., Wu A., Bao J., Xu W., et al. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J. Neuroimmunol. 2011, 240-241:104-108.
63. Alvarez E., Piccio L., Mikesell R.J., Klawiter E.C., Parks B.J., Naismith R.T., et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Multiple Sclerosis 2013, 19(9):1204-1208.
64. Wang H., Wang K., Zhong X., Qiu W., Dai Y., Wu A., et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J. Clin. Immunol. 2012, 32(5):1007-1011.
65. Vladic A., Horvat G., Vukadin S., Sucic Z., Simaga S. Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine 2002, 20(2):86-89.
66. Hauser S.L., Doolittle T.H., Lincoln R., Brown R.H., Dinarello C.A. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 1990, 40(11):1735-1739.
67. Szczucinski A., Losy J. CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis. NeuroImmunoModulation 2011, 18(1):67-72.
68. Romme Christensen J., Bornsen L., Khademi M., Olsson T., Jensen P.E., Sorensen P.S., et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Multiple Sclerosis 2013, 19(7):877-884.
69. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 1999, 103(6):807-815.
70. Kleine T.O., Zwerenz P., Graser C., Zofel P. Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-alpha, IL-1beta, IL-6, IL-8. Brain Res. Bull. 2003, 61(3):327-346.
71. Maimone D., Gregory S., Arnason B.G., Reder A.T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J. Neuroimmunol. 1991, 32(1):67-74.
72. Carrieri P.B., Provitera V., De Rosa T., Tartaglia G., Gorga F., Perrella O. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol. Immunotoxicol. 1998, 20(3):373-382.
73. Navikas V., Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J. Neurosci. Res. 1996, 45(4):322-333.
74. Wen S.R., Liu G.J., Feng R.N., Gong F.C., Zhong H., Duan S.R., et al. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 2012, 244(1-2):94-96.
75. Bielekova B., Komori M., Xu Q., Reich D.S., Wu T. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One 2012, 7(11):e48370.
76. Krumbholz M., Theil D., Cepok S., Hemmer B., Kivisakk P., Ransohoff R.M., et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain: J. Neurol. 2006, 129(Pt 1):200-211.
77. Ragheb S., Li Y., Simon K., VanHaerents S., Galimberti D., De Riz M., et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Multiple Sclerosis 2011, 17(7):819-829.
78. Pranzatelli M.R., Tate E.D., McGee N.R., Colliver J.A. Cytokines, cytokine antagonists, and soluble adhesion molecules in pediatric OMS and other neuroinflammatory disorders. J. Neurol. Sci. 2013, 326(1-2):53-58.
79. Pranzatelli M.R., Tate E.D., McGee N.R., Travelstead A.L., Verhulst S.J., Ransohoff R.M. Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome. Clin. Exp. Immunol. 2013, 172(3):427-436.
80. Pranzatelli M.R., Tate E.D., Hoefgen E.R., Swan J.A., Colliver J.A. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome. Cytokine 2008, 44(1):26-32.
81. Pranzatelli M.R., Tate E.D., McGee N.R., Travelstead A.L., Ransohoff R.M., Ness J.M., et al. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS. J. Neuroimmunol. 2012, 243(1-2):81-88.
82. Tekgul H., Polat M., Kitis O., Serdaroglu G., Tosun A., Terlemez S., et al. T-cell subsets and interleukin-6 response in Rasmussen's encephalitis. Pediatr. Neurol. 2005, 33(1):39-45.
83. Takahashi Y., Mine J., Kubota Y., Yamazaki E., Fujiwara T. A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNFalpha, and Granzyme B in CSF. Epilepsia 2009, 50(6):1419-1431.
84. Dellalibera-Joviliano R., Dos Reis M.L., Cunha Fde Q., Donadi E.A. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J. Rheumatol. 2003, 30(3):485-492.
85. Trysberg E., Carlsten H., Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000, 9(7):498-503.
86. Santer D.M., Yoshio T., Minota S., Moller T., Elkon K.B. Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J. Immunol. 2009, 182(2):1192-1201.
87. Lu X.Y., Zhu C.Q., Qian J., Chen X.X., Ye S., Gu Y.Y. Intrathecal cytokine and chemokine profiling in neuropsychiatric lupus or lupus complicated with central nervous system infection. Lupus 2010, 19(6):689-695.
88. Fragoso-Loyo H., Richaud-Patin Y., Orozco-Narvaez A., Davila-Maldonado L., Atisha-Fregoso Y., Llorente L., et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007, 56(4):1242-1250.
89. Iikuni N., Okamoto H., Yoshio T., Sato E., Kamitsuji S., Iwamoto T., et al. Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus. Ann. Rheum. Dis. 2006, 65(2):253-256.
90. George-Chandy A., Trysberg E., Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res. Ther. 2008, 10(4):R97.
91. Fragoso-Loyo H., Cabiedes J., Richaud-Patin Y., Orozco-Narvaez A., Diamond B., Llorente L., et al. Inflammatory profile in the cerebrospinal fluid of patients with central neuropsychiatric lupus, with and without associated factors. Rheumatology 2009, 48(12):1615-1616.
92. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2001, 2(9):764-766.
93. Hopia L., Thangarajh M., Khademi M., Laveskog A., Wallstrom E., Svenungsson E., et al. Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus. Scand. J. Rheumatol. 2011, 40(5):363-372.
94. Jonsen A., Bengtsson A.A., Nived O., Ryberg B., Truedsson L., Ronnblom L., et al. The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus 2003, 12(11):846-850.
95. Shiozawa S., Kuroki Y., Kim M., Hirohata S., Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum. 1992, 35(4):417-422.
96. Fragoso-Loyo H., Atisha-Fregoso Y., Nunez-Alvarez C.A., Llorente L., Sanchez-Guerrero J. Utility of interferon-alpha as a biomarker in central neuropsychiatric involvement in systemic lupus erythematosus. J. Rheumatol. 2012, 39(3):504-509.
97. Church A.J., Dale R.C., Cardoso F., Candler P.M., Chapman M.D., Allen M.L., et al. CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome?. J. Neuroimmunol. 2003, 136(1-2):149-153.
98. Dauvilliers Y., Jaussent I., Lecendreux M., Scholz S., Bayard S., Cristol J.P., et al. Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: a case-control study. Brain Behav. Immun. 2014, 37:260-266.
99. Biber K., Zuurman M.W., Dijkstra I.M., Boddeke H.W. Chemokines in the brain: neuroimmunology and beyond. Curr. Opin. Pharmacol. 2002, 2(1):63-68.
100. Bo S.H., Davidsen E.M., Gulbrandsen P., Dietrichs E., Bovim G., Stovner L.J., et al. Cerebrospinal fluid cytokine levels in migraine, tension-type headache and cervicogenic headache. Cephalalgia: Int. J. Headache 2009, 29(3):365-372.
101. Fujita K., Matsui N., Takahashi Y., Iwasaki Y., Yoshida M., Yuasa T., et al. Increased interleukin-17 in the cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease: a case-control study of rapidly progressive dementia. J. Neuroinflammation 2013, 10:135.
102. Chez M.G., Dowling T., Patel P.B., Khanna P., Kominsky M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr. Neurol. 2007, 36(6):361-365.
103. Pranzatelli M.R., Tate E.D., McGee N.R., Colliver J.A. Pediatric reference ranges for proinflammatory and anti-inflammatory cytokines in cerebrospinal fluid and serum by multiplexed immunoassay. J. Interferon Cytokine Res.: Official J. Int. Soc. Interferon Cytokine Res. 2013, 33(9):523-528.
104. Narita M., Tanaka H., Togashi T., Abe S. Cytokines involved in CNS manifestations caused by Mycoplasma pneumoniae. Pediatr. Neurol. 2005, 33(2):105-109.
105. Saruhan-Direskeneli G., Yentur S.P., Akman-Demir G., Isik N., Serdaroglu P. Cytokines and chemokines in neuro-Behcet's disease compared to multiple sclerosis and other neurological diseases. J. Neuroimmunol. 2003, 145(1-2):127-134.
106. Sellebjerg F., Bornsen L., Khademi M., Krakauer M., Olsson T., Frederiksen J.L., et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73(23):2003-2010.